Enara Bio's purpose is to shine a light on unconventional T cell targets to develop cancer immunotherapies designed to provide lasting benefit for broad patient populations. Our proprietary EDAPT platform enables us to discover a novel and differentiated class of cancer-specific targets from the genomic dark matter, which we call Dark Antigens. We are using our proprietary bispecific T-cell engager platform (EnTiCE) to target Dark Antigens for the treatment of patients with a broad range of solid tumors.
Enara Bio was founded in 2016 and backed by leading financial and corporate strategic investors from the UK, US and EU. The company is based in Oxford, UK.
MNCJobs.co.uk will not be responsible for any payment made to a third-party. All Terms of Use are applicable.